PDCD1 and neoplasm: Furthermore, we demonstrate that pharmacological inhibition of the NANOG/HDAC1 axis with FK228 triggered anti–PD-1 therapy–mediated tumor regression and made immunologically “cold” tumors “hot” by initiating or reinvigorating the antitumor immunity cycle.